A phase II trial with safety lead-in to evaluate the addition of APX005M, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin chemotherapy for the treatment of advanced soft tissue sarcoma.

Matthew Ingham,Shing Mirn Lee,Sahil D. Doshi,Susana Hernandez,Shahnaz Singh-Kandah,Zoe Singer,Ovidiu C. Trifan,Gary K. Schwartz

A phase II trial with safety lead-in to evaluate the addition of APX005M, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin chemotherapy for the treatment of advanced soft tissue sarcoma.

2020

Matthew Ingham
Shing Mirn Lee
Sahil D. Doshi
Susana Hernandez
Shahnaz Singh-Kandah
Zoe Singer
Ovidiu C. Trifan
Gary K. Schwartz

TPS85Background: Soft tissue sarcoma (STS) is a biologically heterogeneous disease for which existing immunotherapy approaches (e.g. anti-PD-1) have shown limited clinical activity. Cytotoxic chemo...

Keywords:

Soft tissue sarcoma
Disease
Doxorubicin
Cancer research
Cytotoxic T cell
Monoclonal antibody
CD40
Immunotherapy
Medicine
Chemotherapy
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations